Results 151 to 160 of about 71,664 (187)

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma. [PDF]

Pharmaceuticals (Basel)
Oakley O, Mahmood U, Ahmad Y, Smyth E.
europepmc   +1 more source

The "ADC-after-ADC" paradigm: navigating cross-resistance and sequencing in breast cancer therapy. [PDF]

Front Oncol
Asare M, Okobi TO, Karass S, Okobi JT, Taiwo E.   +4 more
europepmc   +1 more source

Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer. [PDF]

Ther Adv Med Oncol
Tang W, Zhou Q, Liu J, Hong S.
europepmc   +1 more source

Persistent Ischemia-Like Electrocardiographic Changes in a Young Breast Cancer Patient on Trastuzumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Alizadehasl A, Elahi M, Zangeneh S, Ahmadloo N, Dehghani M, Sayad M.   +5 more
europepmc   +1 more source

A study on the mechanism of action of B7H4 in HER2-positive gastric cancer and its sensitivity to trastuzumab therapy. [PDF]

Transl Cancer Res
Shao Q, Zhang F, Wang W, Huang Z.
europepmc   +1 more source

Immune checkpoint inhibitors plus trastuzumab and chemotherapy for the treatment of advanced HER2-positive gastric and gastroesophageal junction cancers: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhan H, Zhang H, Tian C, Liu P, Sun W.
europepmc   +1 more source

Adjuvant therapies by anthocyanins potentially mitigating drug resistance and metastatic disease risks in stratified breast cancers: the 3PM-conceptual innovation targeted to NF-kappaB/EMT plasticity. [PDF]

EPMA J
Sventekova A, Kubatka P, Slaninova I, Nykodymova D, Hornakova L, Trbolova A, Goncharenko V, Smejkal K, Golubnitschaja O.   +8 more
europepmc   +1 more source

Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis. [PDF]

Oncologist
Nichetti F, Nappo F, Bof F, Bosa M, Mattiuzzo E, Maddalena G, De Grandis MC, Murgioni S, Bergamo F, Lonardi S.   +9 more
europepmc   +1 more source

Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review. [PDF]

Medicina (Kaunas)
Tirinescu R, Pah AM, Tirinescu A, Mateescu DM, Muresan CO.   +4 more
europepmc   +1 more source

The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders. [PDF]

Cancer Cell Int
Ma Y, Wang S, Li X, Guo X, Jiang C, Sun T.   +5 more
europepmc   +1 more source